Hoe verhoudt DPH N's PE Ratio zich tot zijn concurrenten?

DPH N is duur op basis van de Price-To-Earnings -ratio ( 105.6 x) vergeleken met het gemiddelde van de peer ( 28.7 x).

Hoe verhoudt DPH N's PE Ratio zich tot andere bedrijven in de Global Pharmaceuticals industrie?

DPH N is duur op basis van de Price-To-Earnings -ratio ( 105.6 x) vergeleken met het South American Pharmaceuticals -industriegemiddelde ( 8.7 x).

Wat is DPH N's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Earnings Fair Ratio van { DPH N te berekenen voor waarderinganalyse.

Wat is de reële prijs van DPH N als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

DPH N ( MX$858.69 ) handelt boven onze schatting van [[eerlijke waarde]] ( MX$425.81 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Dechra Pharmaceuticals (BMV:DPH N) - Aandelenkoers, Nieuws & Analyse

DPH N Overzicht aandelen

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. Meer informatie

DPH N fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	4/6
Prestaties in het verleden	2/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 21.21% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

De schulden worden niet goed gedekt door de operationele kasstroom

Winstmarges (5.5%) zijn lager dan vorig jaar (11.4%)

Aandeelhouders zijn het afgelopen jaar verwaterd

Dechra Pharmaceuticals PLC Concurrenten

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.7b

Dong-E-E-JiaoLtd

SZSE:000423

CN¥36.4b

Ono Pharmaceutical

TSE:4528

JP¥820.8b

Haisco Pharmaceutical Group

SZSE:002653

CN¥38.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Dechra Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	UK£858.69
52 Week Hoogtepunt	UK£863.85
52 Week Laag	UK£740.83
Bèta	0.71
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	2.09%
33 jaar verandering	34.09%
5 jaar verandering	n/a
Verandering sinds IPO	28.77%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	DPH N	MX Pharmaceuticals	MX Markt
7D	0%	-1.3%	-0.3%
1Y	2.1%	-19.3%	-4.0%

Rendement versus industrie: DPH N overtrof de MX Pharmaceuticals industrie, die het afgelopen jaar een rendement -19.3 % opleverde.

Rendement versus markt: DPH N presteerde slechter dan MX Market, dat het afgelopen jaar een rendement van -4 % opleverde.

Prijsvolatiliteit

Is DPH N's price volatile compared to industry and market?
DPH N volatility
DPH N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.7%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	6.1%
10% least volatile stocks in MX Market	2.7%

Stabiele aandelenkoers: DPH N heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van DPH N in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1997	1,998	Ian Page	www.dechra.com

Dechra Pharmaceuticals PLC Samenvatting

Hoe verhouden de winst en inkomsten van Dechra Pharmaceuticals zich tot de beurswaarde?
DPH N fundamentele statistieken
Marktkapitalisatie	Mex$95.37b
Inkomsten(TTM)	Mex$902.94m
Inkomsten(TTM)	Mex$16.37b

105.6x

Koers/Winstverhouding

5.8x

P/S-verhouding

Is DPH N overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
DPH N resultatenrekening (TTM)
Inkomsten	UK£726.80m
Kosten van inkomsten	UK£312.20m
Brutowinst	UK£414.60m
Overige uitgaven	UK£374.50m
Inkomsten	UK£40.10m

Laatst gerapporteerde inkomsten

Dec 31, 2022

Volgende inkomensdatum

Sep 04, 2023

Winst per aandeel (EPS)	0.35
Brutomarge	57.04%
Nettowinstmarge	5.52%
Schuld/Eigen Vermogen Verhouding	61.8%

Hoe presteerde DPH N op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

1.2%

Huidig dividendrendement

125%

Uitbetalingsratio

DPH N Overzicht aandelen

Beloningen

Risicoanalyse

Dechra Pharmaceuticals PLC Concurrenten

BMV:LAB B

Mex$24.7b

SZSE:000423

CN¥36.4b

TSE:4528

JP¥820.8b

SZSE:002653

CN¥38.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Less than half of directors are independent

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Less than half of directors are independent

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Announces Executive Changes

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Non-Executive Chairman recently bought Mex$2.6m worth of stock

Investor sentiment improved over the past week

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Investor sentiment deteriorated over the past week

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Less than half of directors are independent

Upcoming dividend of UK£0.29 per share

Less than half of directors are independent

Non-Executive Director recently bought Mex$178k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Less than half of directors are independent

Board Member recently sold Mex$27m worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

CEO, MD & Executive Director recently sold Mex$279m worth of stock

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Non-Executive Director recently bought Mex$712k worth of stock

Independent Non Executive Director recently sold Mex$3.5m worth of stock

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Dechra Pharmaceuticals PLC Samenvatting

105.6x

5.8x

Inkomsten en omzet